INVO Bioscience, Inc.
INVO
$2.07
$0.239913.11%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 481.39% | 352.96% | 396.87% | 314.32% | 116.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 481.39% | 352.96% | 396.87% | 314.32% | 116.22% |
| Cost of Revenue | 265.55% | 268.05% | 278.01% | 133.33% | 38.24% |
| Gross Profit | 1,115.59% | 520.60% | 1,035.32% | 2,975.18% | 428.69% |
| SG&A Expenses | 29.61% | -38.19% | -30.44% | -45.74% | -16.44% |
| Depreciation & Amortization | 1,069.04% | 1,088.48% | 611.56% | 4.06% | -10.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.00% | -4.96% | -3.54% | -32.58% | -15.77% |
| Operating Income | 7.89% | 58.97% | 44.51% | 64.90% | 22.96% |
| Income Before Tax | -0.34% | 37.48% | 28.69% | 51.11% | 20.11% |
| Income Tax Expenses | -- | -- | 995.24% | -- | 262.50% |
| Earnings from Continuing Operations | -0.21% | 37.41% | 27.91% | 51.04% | 20.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.21% | 37.41% | 27.91% | 51.04% | 20.02% |
| EBIT | 7.89% | 58.97% | 44.51% | 64.90% | 22.96% |
| EBITDA | 18.26% | 68.55% | 49.34% | 65.45% | 23.06% |
| EPS Basic | 79.67% | 89.75% | 85.94% | 83.25% | 33.84% |
| Normalized Basic EPS | 79.56% | 92.76% | 87.88% | 83.27% | 33.91% |
| EPS Diluted | 79.67% | 89.76% | 85.94% | 83.25% | 33.83% |
| Normalized Diluted EPS | 79.56% | 92.76% | 87.88% | 83.27% | 33.91% |
| Average Basic Shares Outstanding | 392.94% | 510.75% | 412.65% | 192.35% | 20.88% |
| Average Diluted Shares Outstanding | 392.94% | 510.75% | 412.65% | 192.35% | 20.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
